Table 2 Correlation between Trx1 level and clinicopathological characteristics in breast cancer patients and women without cancer
From: The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer
Correlation between Trx1 level and age in breast cancer patients and women without cancer | |||||
Variable | Age | Trx1 (95% CI) | No. | % | P Value |
Women without cancer | 30s | 3.16(1.16 to 5.16) | 3 | 2.6 | 0.6689 |
(n = 114) | 40s | 5.99(4.06 to 7.91) | 14 | 12.3 | |
50s | 6.31(4.67 to 7.95) | 30 | 26.3 | ||
60s | 4.84(3.55 to 6.12) | 36 | 31.6 | ||
70s | 5.29(3.44 to 7.15( | 29 | 25.4 | ||
80s | 5.25(NA) | 2 | 1.8 | ||
Breast cancer patients | 30s | 22.60 (16.0 to 29.2) | 7 | 6.6 | 0.705 |
(n = 106) | 40s | 22.85 (20.5 to 25.2) | 47 | 44.3 | |
50s | 20.75 (19.22 to 22.27) | 42 | 39.6 | ||
60s | 22.44 (17.0 to 27.82) | 10 | 9.4 | ||
Correlation between Trx1 level and clinicopathological characteristics in breast cancer patientsa | |||||
Variable | Trx1(95% CI) | No. (n = 106) | % | P Value | |
Histologic grade | 1 | 22.08 (19.61 to 24.55) | 24 | 22.6 | 0.8422 |
2 | 21.19 (19.54 to 22.84) | 51 | 48.1 | ||
3 | 23.14 (19.95 to 26.32) | 31 | 29.3 | ||
Histologic subtypes | DCIS | 22.25 (NA) | 2 | 1.9 | 0.5083 |
IDC | 22.00 (20.54 to 23.45) | 92 | 86.8 | ||
ILC | 24.63 (19.78 to 29.48) | 5 | 4.7 | ||
MC | 20.41 (13.78 to 27.03) | 5 | 4.7 | ||
IMPC | 19.07 (NA) | 1 | 0.9 | ||
ITC | 15.55 (NA) | 1 | 0.9 | ||
Molecular subtypes | Luminal A | 20.18 (18.44 to 21.92) | 47 | 44.3 | 0.1043 |
Luminal B | 23.31 (20.69 to 25.92) | 37 | 34.9 | ||
TNBC | 24.45 (20.92 to 27.98) | 13 | 12.3 | ||
HER2-enriched | 22.15 (17.43 to 26.87) | 9 | 8.5 | ||
TNM Stage | 0 | 22.25 (NA) | 2 | 1.9 | 0.4383 |
1 | 21.64 (19.48 to 23.8) | 37 | 35 | ||
2 | 21.94 (20.22 to 23.66) | 50 | 47.2 | ||
3 | 21.86 (16.46 to 27.26) | 15 | 14.2 | ||
4 | 28.97 (NA) | 2 | 1.9 | ||
Ki67 | < 15% | 21.52 (20.06 to 22.97) | 49 | 46.2 | 0.7368 |
≥15% | 22.34 (20.22 to 24.47) | 57 | 53.8 | ||